Biotech News
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
investors.beamtx.com2026-05-07 11:04 EST
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel